Management of Methotrexate Toxicity

Recognition of Toxicity Types

• The American Academy of Dermatology notes that common minor toxicities include nausea, anorexia, stomatitis, and fatigue that typically occur around the time of methotrexate administration 1, 2
• Major life-threatening toxicities include myelosuppression, pulmonary fibrosis, and hepatotoxicity, as reported by the American Academy of Dermatology 1, 3
• Pulmonary toxicity should be suspected in patients with new pulmonary symptoms such as dry cough, which is more common in rheumatoid arthritis than psoriasis patients, according to the American Academy of Dermatology 1, 4

Risk Factors for Methotrexate Toxicity

• Renal insufficiency is a primary risk factor due to impaired drug clearance, as noted by the American Academy of Dermatology 3
• Advanced age is a risk factor for methotrexate toxicity, as reported by the American Academy of Dermatology 3, 4
• Lack of folate supplementation increases the risk of methotrexate toxicity, according to the American Academy of Dermatology 1, 5
• Methotrexate dosing errors can lead to toxicity, as noted by the American Academy of Dermatology 3
• Drug interactions, especially with NSAIDs and sulfonamides, can increase the risk of methotrexate toxicity, as reported by the American Academy of Dermatology 3, 4

Immediate Management of Methotrexate Overdose

• The American College of Medical Toxicology recommends administering leucovorin (folinic acid) as soon as possible, which is life-saving and time-critical 6
• For recent oral ingestion of ≥1 mg/kg, activated charcoal should be administered, as recommended by the American College of Medical Toxicology 6
• Aggressive hydration with intravenous fluids should be initiated, as noted by the American College of Medical Toxicology 6
• Urinary alkalinization with sodium bicarbonate should be performed to prevent methotrexate precipitation in renal tubules, as recommended by the American College of Medical Toxicology 6

Management of Specific Toxicities

Hematologic Toxicity

• Complete blood counts should be monitored closely, as recommended by the American Academy of Dermatology 3
• If total white cells <3.5×10^9/L or neutrophils <2×10^9/L, methotrexate should be withheld until counts recover, according to the European Society of Gastrointestinal Endoscopy 7
• For severe neutropenia (<1×10^9/L), patients should be warned to present for antibiotics ± GCSF if febrile, as recommended by the European Society of Gastrointestinal Endoscopy 7

Hepatotoxicity

• Liver function tests should be monitored regularly, as recommended by the European Society of Gastrointestinal Endoscopy 7
• If transaminases exceed twice the upper limit of normal, methotrexate should be stopped, according to the European Society of Gastrointestinal Endoscopy 7

Pulmonary Toxicity

• A baseline chest x-ray should be obtained for all patients starting methotrexate, as recommended by the European Society of Gastrointestinal Endoscopy 7, 4
• Patients should be monitored for symptoms of interstitial pneumonitis (dyspnea, dry cough, fever), as noted by the American College of Medical Toxicology 4

Prevention of Toxicity

• All patients on methotrexate should receive folate supplementation (1-5 mg daily, except on the day of methotrexate administration), as recommended by the American Academy of Dermatology 1, 5
• Regular monitoring of complete blood counts, liver function tests, and renal function is essential, as noted by the American College of Medical Toxicology 5

Tratamiento de la Intoxicación por Metotrexato

Reconocimiento y Evaluación Inicial

• Los factores de riesgo para toxicidad incluyen insuficiencia renal, edad avanzada, errores de dosificación, interacciones medicamentosas, falta de suplementación con folato e hipoalbuminemia, según la American Academy of Dermatology 8

Manejo de Toxicidades Específicas

Toxicidad Hepática

• En pacientes con elevación persistente de enzimas hepáticas durante un período de 12 meses o una disminución de la albúmina sérica por debajo del rango normal, considerar una consulta con gastroenterología y/o biopsia hepática, según la American Academy of Dermatology 8

Prevención de Toxicidad

• Revisar constantemente los medicamentos del paciente para identificar posibles interacciones que puedan aumentar la toxicidad del metotrexato, según la American Academy of Dermatology 8

Management of Methotrexate Toxicity

Introduction to Methotrexate Toxicity Management

• Myelosuppression accounts for the majority of methotrexate-associated fatalities, with 67 out of 164 reported cases, according to the American Academy of Dermatology 9
• Pulmonary fibrosis accounts for 30 out of 164 methotrexate-associated fatalities, as reported by the American Academy of Dermatology 9

Management of Specific Toxicity Types

• The British Society of Gastroenterology recommends stopping methotrexate immediately if transaminases exceed twice the upper limit of normal 10
• Liver function abnormalities can be transitory, with many normalizing without stopping methotrexate, and only 5% requiring permanent discontinuation, as suggested by the British Society of Gastroenterology 10
• For patients with BMI >28 kg/m² or alcohol intake >14 drinks per week, the British Society of Gastroenterology recommends screening using transient elastography (FibroScan) 10
• Routine liver biopsy after prolonged use is not necessary, as cirrhosis risk is much lower than previously thought, according to the British Society of Gastroenterology 10
• The British Society of Gastroenterology recommends obtaining a baseline chest x-ray for all patients starting methotrexate 10
• Monitor for acute interstitial pneumonitis presenting with dyspnea, dry cough, and fever, as suggested by the British Society of Gastroenterology 10

Prevention Strategies

• The British Society of Gastroenterology recommends that all patients on methotrexate must receive folate supplementation to reduce gastrointestinal, liver, and hematologic toxicity 10
• Folate supplementation dosing options include 1 mg daily or 5 mg weekly, as recommended by the British Society of Gastroenterology 10
• The British Society of Gastroenterology suggests baseline testing, including FBC, U&E, LFT, and chest x-ray 10
• Monitoring frequency should be weeks 2, 4, 8, and 12 after initiation, and at least every 3 months thereafter, as recommended by the British Society of Gastroenterology 10
• Minimize common minor toxicities, such as nausea, anorexia, stomatitis, and fatigue, by administering methotrexate by intramuscular or subcutaneous injection, splitting the dose, ensuring folate supplementation, and administering with food or at bedtime, as suggested by the American Academy of Dermatology 9

Management of Methotrexate Toxicity

Monitoring and Prevention

• The American Academy of Dermatology recommends monitoring liver function tests every 3-6 months during chronic methotrexate therapy 11
• According to the Annals of Emergency Medicine, pulmonary symptoms usually resolve with discontinuation of methotrexate, and it is essential to obtain a baseline chest x-ray for all patients starting methotrexate 12
• The Annals of Emergency Medicine also suggests that in patients treated for ectopic pregnancy, gastrointestinal symptoms may mimic acute ectopic rupture, and treatment failure should be ruled out before attributing symptoms to methotrexate toxicity 12
• Additionally, the Annals of Emergency Medicine recommends avoiding folic acid during high-dose methotrexate treatment for ectopic pregnancy, as it may counteract the therapeutic effect 12

Methotrexate-Associated Gastrointestinal Irritation

Introduction to Methotrexate Toxicity

• Methotrexate is gastrointestinal irritating, with GI symptoms occurring in approximately 30-32% of patients, making it one of the most common adverse effects of this medication 13

Management and Prevention Strategies

• The British Society of Gastroenterology and American Academy of Dermatology strongly recommend folic acid supplementation (1 mg daily or 5 mg weekly) to reduce GI toxicity 13
• The American Academy of Dermatology suggests splitting the weekly dose (e.g., divide into two doses 12 hours apart) 13
• The American Academy of Dermatology also suggests administering methotrexate with food or at bedtime, and altering dosing frequency 13

Special Populations and Considerations

• Primary side effects in children include stomatitis and gastrointestinal irritation 14, 15
• In a Spanish nationwide database of nearly 4000 IBD patients, nausea occurred in 8% of those on thiopurines 13
• Methotrexate has comparable safety to thiopurines in IBD patients 13

Folate Deficiency Diagnosis and Management

Clinical Presentation and Diagnosis

• The American Academy of Dermatology recommends that patients on methotrexate be monitored for signs of folate deficiency, including macrocytic anemia, which can present with severe anemia and symptoms such as progressive fatigue and shortness of breath 16, 17
• Methotrexate-induced folate deficiency can cause macrocytic anemia with normal or low reticulocytes, and the European consensus on anemia classification lists long-term cytostatic medication, including methotrexate, as a cause of this condition 17
• The European guidelines state that anemia of chronic disease typically presents with normocytic or microcytic anemia, not macrocytic anemia, and has a serum ferritin >100 μg/L and transferrin saturation <20% 17

Management and Prevention

• The American Academy of Dermatology recommends that all patients on methotrexate receive folate supplementation (1-5 mg daily, except on the day of methotrexate administration) to prevent gastrointestinal, liver, and hematologic toxicity 16
• The British Society of Gastroenterology also recommends folate supplementation for patients on methotrexate, and regular monitoring with complete blood counts every 3-4 months is essential to detect early signs of folate deficiency and impending toxicity 16, 18
• In cases of suspected methotrexate-induced folate deficiency, the American Academy of Dermatology recommends immediate discontinuation of methotrexate and administration of leucovorin (folinic acid) as an antidote, as well as checking complete blood count with differential to assess for pancytopenia 16, 18

Methotrexate-Induced Megaloblastic Anemia

Prevention and Management

• The American College of Rheumatology recommends that all patients on methotrexate receive folate supplementation (1 mg daily or 5 mg weekly, except on the day of methotrexate administration) to prevent gastrointestinal, liver, and hematologic toxicity 19
• Regular monitoring with complete blood counts every 3-4 months is essential to detect early signs of folate deficiency and impending toxicity, with an increase in MCV as a useful early indicator of folate deficiency before severe anemia develops 19

Risk Factors

• Advanced age (over 50 years) increases the risk of methotrexate toxicity 19
• Lack of folate supplementation is a common preventable risk factor for methotrexate toxicity 19

Methotrexate Toxicity Management

Overview and Clinical Recognition

• Methotrexate aminopterin syndrome manifests with mucositis, fever, diarrhea, erythema, ulceration, and rarely cutaneous necrolysis, typically appearing 6-23 days after exposure, with myelosuppression accounting for the majority of methotrexate-associated fatalities, making hematologic toxicity the most lethal complication 20

Immediate Management Protocol

• Leucovorin (folinic acid) administration is the cornerstone of treatment and must be initiated immediately upon suspicion of methotrexate toxicity, as efficacy diminishes dramatically after 24 hours, with initial dosing of up to 100 mg/m² IV if methotrexate level is unknown, followed by doses every 6 hours (oral or IV) until methotrexate levels fall below 0.05 µmol/L 20
• For recent ingestion (≥1 mg/kg within 1 hour), administer activated charcoal immediately, and initiate IV fluids to enhance renal elimination of methotrexate, with urinary alkalinization using sodium bicarbonate to prevent methotrexate precipitation in renal tubules 20

Management of Specific Toxicities

• For life-threatening bone marrow suppression, filgrastim (G-CSF) should be administered subcutaneously at 5 µg/kg daily to accelerate myeloid recovery, with monitoring for sepsis with high vigilance, as mortality risk is substantial 20

Critical Drug Interactions

• Trimethoprim-sulfamethoxazole is absolutely contraindicated with methotrexate due to severe bone marrow suppression risk, with other high-risk interactions including NSAIDs, which reduce renal elimination, particularly dangerous with high-dose methotrexate 21

Special Considerations

• If plasma methotrexate levels remain elevated despite standard measures, carboxypeptidase G2 should be obtained from the National Institutes of Health on a compassionate-use basis, with consideration of MTHFR genotyping to identify individuals with diminished enzyme activity at increased risk for toxicity 22

Prevention of Errors

• Delaying leucovorin administration is a common pitfall, as efficacy is doubtful if initiated >24 hours after last methotrexate dose, and assuming low serum levels exclude toxicity is also incorrect, as serum methotrexate levels do not correlate with toxicity; treat based on clinical presentation 20
• Administering folic acid instead of folinic acid is another pitfall, as only leucovorin (folinic acid) bypasses methotrexate's metabolic block, and stopping antibiotics prematurely is also a mistake, as methotrexate should remain discontinued until infection resolves and antibiotic course is complete 20, 21

Risk of Toxicity from Accidental Twice-Weekly Methotrexate Dosing

Patient Risk Factors

• Patients with renal insufficiency are at risk of toxicity even after single doses of methotrexate, according to the American Academy of Dermatology 23
• Unusual fatigue or malaise can be a warning sign of toxicity in patients who have taken methotrexate, as noted by the American Academy of Dermatology 23
• Fever or chills can be a symptom of toxicity in patients who have taken methotrexate, as reported by the American Academy of Dermatology 23

Management of Toxicity

• The American College of Medical Toxicology recommends leucovorin (folinic acid) as a life-saving antidote for methotrexate toxicity, which must be administered immediately 23

Prevention of Future Errors

• The European League Against Rheumatism recommends ensuring folic acid supplementation of at least 5mg weekly to prevent methotrexate toxicity 24

Leucovorin Dosing for Oral Methotrexate Toxicity

Immediate Dosing Protocol

• The American Academy of Dermatology recommends administering leucovorin at 10 mg/m² (approximately 15 mg for average adult) immediately, with subsequent doses given every 6 hours until toxicity resolves, for patients with suspected or confirmed oral methotrexate toxicity 25
• The American Academy of Dermatology specifically recommends a standard rescue dose of leucovorin 15 mg intravenously or orally every 6 hours, as efficacy diminishes dramatically with delayed administration, for patients with suspected oral methotrexate toxicity 25

Common Pitfalls to Avoid

• The American Academy of Dermatology advises not to confuse folic acid with folinic acid (leucovorin), as only leucovorin bypasses methotrexate's metabolic block and serves as an effective antidote, and folic acid supplementation is for prevention, not treatment of acute toxicity 25, 26

Management of Methotrexate Toxicity

Patient-Related Risk Factors

• The American Academy of Dermatology notes that advanced age (>50-70 years) significantly increases toxicity risk, and renal insufficiency is the primary risk factor due to impaired drug clearance, with lack of folate supplementation and hypoalbuminemia also increasing toxicity risk 27
• The American Academy of Dermatology recommends monitoring liver function tests closely, repeating in 2-4 weeks, as liver function abnormalities can be transitory 27

Management of Methotrexate Toxicity

Risk Factors and Prevention

• Renal insufficiency is a critical risk factor for methotrexate toxicity due to 85% renal excretion, and patients with renal insufficiency require enhanced monitoring and lower thresholds for intervention, according to the American Academy of Dermatology 28
• NSAIDs reduce renal elimination of methotrexate, which is particularly dangerous with any dose of methotrexate, as reported by the American Academy of Dermatology 28
• The American Academy of Dermatology and the Gut journal recommend that patients with high-risk factors, such as renal insufficiency, advanced age, and lack of folate supplementation, require enhanced monitoring and lower thresholds for intervention 28, 29

Management of Specific Toxicities

• The Gut journal recommends withholding methotrexate if WBC <3.5×10⁹/L, neutrophils <2×10⁹/L, or platelets <100×10⁹/L, and administering filgrastim (G-CSF) 5 µg/kg subcutaneously daily for severe neutropenia (<1×10⁹/L) 29
• The Gut journal suggests stopping methotrexate if transaminases exceed 2× upper limit of normal on repeat testing, and performing transient elastography (FibroScan) screening for patients with BMI >28 kg/m² or alcohol intake >14 drinks/week 29
• The Gut journal recommends suspecting pulmonary toxicity in patients presenting with dyspnea, dry cough, and fever, and obtaining chest X-ray immediately, as pulmonary fibrosis accounts for 30 of 164 methotrexate-associated fatalities 29

Prevention of Future Toxicity

• The Gut journal recommends mandatory folic acid supplementation of 1-5 mg daily (except on methotrexate day) or 5 mg weekly, and enhanced monitoring schedule after restart of methotrexate 29
• The American Academy of Dermatology and the Gut journal recommend that women should avoid conception for 6 months after stopping methotrexate, and men should wait 3 months after discontinuation before attempting conception 28, 29

Methotrexate Monitoring Guidelines

Introduction to Methotrexate Monitoring

• The American Academy of Dermatology recommends that serum methotrexate level monitoring is not routinely necessary for patients with rheumatoid arthritis or psoriasis receiving standard low-dose weekly methotrexate therapy 30

Monitoring Schedule

• For the first 3 months, the American Academy of Dermatology recommends complete blood count, liver function tests, and creatinine at least monthly 30
• After stabilization, the American Academy of Dermatology recommends complete blood count and liver function tests every 3-6 months 30

Hepatotoxicity Monitoring

• The American Academy of Dermatology emphasizes that baseline liver biopsy is not recommended regardless of risk factors 30
• For patients without risk factors for hepatotoxicity, the American Academy of Dermatology recommends monitoring liver function tests monthly for the first 6 months, then every 1-3 months 31
• For patients with risk factors for hepatotoxicity, the American Academy of Dermatology recommends GI/hepatology consult and/or vibration-controlled transient elastography (FibroScan) at baseline 30

Critical Recommendations

• The American Academy of Dermatology recommends ensuring mandatory folic acid supplementation, with at least 5 mg folic acid weekly or 1 mg daily except on methotrexate day, to reduce toxicity risk 30

Risk of Toxicity from Accidental Twice-Weekly Methotrexate Dosing

Patient Risk Factors

• Advanced age is a primary risk factor for methotrexate toxicity, with elderly patients showing increased susceptibility to severe complications, as noted by the British Journal of Dermatology 32

Expected Timeline of Toxicity

• Symptoms typically manifest 6-23 days after the dosing error begins, with common early manifestations including mucositis, oral ulceration, fever, malaise, nausea, vomiting, diarrhea, and myelosuppression, according to the British Journal of Dermatology 32

Immediate Management Protocol

• The British Association of Dermatologists recommends immediate hospital admission for evaluation and monitoring, with measurement of serum methotrexate levels at least 4 hours after last ingestion, and administration of leucovorin (folinic acid) rescue therapy as soon as possible, as stated in the British Journal of Dermatology 32
• Leucovorin must be administered as soon as possible, with efficacy diminishing dramatically after 24 hours, and is doubtful if initiated later than 24 hours after the last methotrexate dose, as noted by the British Journal of Dermatology 32
• Aggressive IV hydration and urinary alkalinization with sodium bicarbonate are recommended to enhance renal elimination and prevent methotrexate precipitation in renal tubules, according to the British Journal of Dermatology 32

Prevention of Future Errors

• The British Journal of Dermatology recommends prescribing only 2.5mg tablets to make daily dosing physically impossible, writing dose in full uppercase letters, and using patient-held record books documenting weekly dosing schedule, to prevent future dosing errors 32
• The Journal of the American Academy of Dermatology suggests ensuring mandatory folic acid supplementation of at least 5mg weekly on a different day than methotrexate, to reduce the risk of toxicity 33

Special Considerations

• Prior radiation therapy may compound mucositis severity, as noted by the Journal of the American Academy of Dermatology 33
• The British Journal of Dermatology recommends close monitoring for signs of sepsis and treatment accordingly, in patients with severe symptoms 32

Management of Methotrexate Toxicity

Special Considerations

• The American Gastroenterological Association recommends that if conception occurs while taking methotrexate, the drug should be stopped immediately and folic acid supplementation should be initiated or continued, as methotrexate is a known teratogen 34
• The American Gastroenterological Association also states that termination of pregnancy is not mandatory if conception occurs while taking methotrexate, and patients should be referred to an obstetrician to discuss risks of teratogenicity and further management 34

Methotrexate Side Effects and Management

Introduction to Methotrexate Toxicity

• The American Academy of Dermatology recommends that patients with preexisting pulmonary disease may not be candidates for methotrexate 35
• Methotrexate is 85% renally excreted, making renal function critical for safe elimination, and patients with impaired renal function require marked dose reduction or discontinuation 36

Special Populations at Increased Risk

• The American Academy of Dermatology suggests that liver biopsy should be performed before or shortly after therapy initiation in patients with preexisting liver damage or impaired hepatic function 36
• Patients with renal impairment have a dramatically increased toxicity risk due to methotrexate accumulation, leading to prolonged exposure and enhanced toxicity 36

Critical Drug Interactions Increasing Toxicity

• The American Academy of Dermatology warns that NSAIDs reduce renal elimination of methotrexate, leading to elevated drug levels and increased toxicity risk 36
• Other high-risk interactions include salicylates, sulfonamides, penicillins, probenecid, and colchicine, which decrease methotrexate binding to albumin or reduce renal tubular excretion 36

Essential Prevention Strategies

• The American Academy of Dermatology recommends mandatory folic acid supplementation to reduce gastrointestinal, hepatic, and hematologic toxicity without compromising efficacy 35
• Regular laboratory monitoring, including baseline and periodic CBC, liver function tests, and creatinine, is essential for patients on methotrexate 36

Bone Marrow Recovery Time from Methotrexate Toxicity

Factors Influencing Recovery Time

• The American Academy of Dermatology notes that lack of folate supplementation impairs recovery, and risk factors such as renal insufficiency, advanced age, and hypoalbuminemia may prolong recovery 37

Treatment Interventions That Accelerate Recovery

• The use of leucovorin (folinic acid) rescue, with standard dosing of 15 mg IV or PO every 6 hours until toxicity resolves, is critical in accelerating recovery, although the exact protocol may vary depending on the severity of toxicity and methotrexate levels 37

Methotrexate Weekly Dosing, Dose Splitting, and Folic Acid Supplementation Guidelines

1. Dosing Frequency Requirements

2. Comparative Efficacy of Weekly vs. Daily Regimens

3. Strategies for Managing Persistent Gastrointestinal Intolerance

4. Mandatory Folic Acid Supplementation

Methotrexate Clinical Guidelines (Evidence‑Based)

Mechanism of Action

• Methotrexate acts as a folic‑acid antagonist by inhibiting dihydrofolate reductase, which blocks purine and pyrimidine synthesis and impairs DNA production in rapidly dividing cells such as B‑ and T‑lymphocytes and malignant cells. 40
• This inhibition leads to depletion of intracellular tetrahydrofolate, a cofactor essential for DNA replication and repair. 41

Indications (Standard‑Dose 7.5–25 mg weekly)

• Moderate‑to‑severe psoriasis in adults – recommended with a strength‑of‑recommendation “A” by the American Academy of Dermatology (AAD). 42
• Psoriatic arthritis (peripheral joint disease) – methotrexate is used, though it is less effective than TNF‑inhibitors. 42

Dosing & Administration

• The weekly dose may be administered as a single injection or divided into 2–3 doses over a 24‑hour period to improve gastrointestinal tolerability. 42
• Subcutaneous or intramuscular routes can be employed; they improve bioavailability and reduce side‑effect frequency compared with oral dosing. 42
• In patients with impaired renal function, a test dose should be considered before full‑dose initiation. 42

Toxicity Profile & Monitoring

• Gastro‑intestinal adverse effects (nausea, vomiting, diarrhea, stomatitis) are the most common, occurring in approximately 25‑32 % of treated patients. 40
• Bone‑marrow suppression (leukopenia, thrombocytopenia, anemia) is a serious toxicity that must be monitored. 40
• Hepatic monitoring: If transaminases rise to >2 × the upper limit of normal on repeat testing, methotrexate should be stopped and liver enzymes re‑checked in 2–4 weeks. 42
• Routine laboratory surveillance: After dose stabilization, complete blood count (CBC) and liver function tests are recommended every 3–6 months. 42

Folate Supplementation (Prevention of Toxicity)

• All patients should receive folic‑acid supplementation (1–5 mg daily, omitted on the day of methotrexate administration, or 5 mg weekly on a different day) to reduce gastrointestinal, hepatic, and hematologic toxicity. [40][41]42
• Very high folic‑acid doses may diminish methotrexate efficacy; therefore, dosing should be balanced according to guideline recommendations. 42

Contraindications

• Pregnancy and breastfeeding are absolute contraindications because methotrexate is a known teratogen; this recommendation is endorsed by the American Academy of Dermatology. 42

All facts are derived from peer‑reviewed sources and reflect the strength of evidence where specified.

Methotrexate Safety Monitoring and Management Guidelines

Common Adverse Effects and Mitigation

• Gastro‑intestinal toxicity (nausea, vomiting, stomatitis, anorexia, abdominal distress) occurs in ≈ 25‑32 % of patients receiving methotrexate. The American Academy of Dermatology notes this frequency. 43
• Switching the route of administration (e.g., oral → subcutaneous or intramuscular) or dividing the weekly dose into 2‑3 administrations over 24 h can improve tolerability of methotrexate‑related side effects. 43
• Taking methotrexate with food or at bedtime reduces gastrointestinal symptoms. 43
• Mandatory folic‑acid supplementation (1–5 mg daily, omitted on the methotrexate day, or 5 mg weekly on a separate day) reduces gastrointestinal, hepatic, and hematologic toxicity without compromising efficacy. Supported by both the American Academy of Dermatology and the Annals of the Rheumatic Diseases. [43][44]

Hepatotoxicity

• Elevations of liver enzymes are common, observed in 48.9 % of patients (values above the upper limit of normal). Severe fibrosis occurs in 1.3 % and cirrhosis in 0.5 % after a mean exposure of 4.1 years. Evidence from the Annals of the Rheumatic Diseases. 44
• Methotrexate should be discontinued if ALT or AST rise > 3 × the upper limit of normal; therapy may be resumed at a lower dose after normalization. 44
• If ALT/AST remain ≤ 3 × ULN but are persistently elevated, the dose should be adjusted and further diagnostic evaluation (e.g., gastro‑intestinal consultation, transient elastography) considered. Evidence from both the Annals of the Rheumatic Diseases and the American Academy of Dermatology. [44][43]

Pulmonary Toxicity

• Methotrexate‑induced pneumonitis typically presents with dyspnea, a dry non‑productive cough, and fever. Documented by the American Academy of Dermatology. 43
• The incidence of pulmonary toxicity is higher in patients with rheumatoid arthritis than in those with psoriasis. 43

Infection and Immunosuppression

• Methotrexate therapy increases the risk of infections, reactivation of latent tuberculosis and hepatitis B/C, and lymphoproliferative disorders (especially EBV‑associated B‑cell lymphoma). Evidence from the American Academy of Dermatology. 43
• Baseline screening for hepatitis B/C and tuberculosis should be performed based on individual risk factors before initiating methotrexate. 43

Major Risk Factors for Toxicity

• Renal insufficiency is the primary risk factor because approximately 85 % of methotrexate is renally excreted, and impaired clearance markedly raises toxicity risk. Supported by the American Academy of Dermatology. 43

Monitoring Requirements

Initial Phase (first 3–6 months)

• During dose initiation or escalation, obtain complete blood count with differential, ALT/AST, serum creatinine, and albumin every 1–1.5 months until a stable dose is achieved. Evidence from the Annals of the Rheumatic Diseases. 44
• Baseline evaluation should include CBC with differential and platelet count, hepatic enzymes, renal function tests, chest radiograph, and consideration of hepatitis B/C and tuberculosis screening. 43

Maintenance Phase

• After stabilization, repeat CBC and liver function tests every 1–3 months (some guidelines allow every 3–6 months). Evidence from the Annals of the Rheumatic Diseases. 44
• Perform a clinical assessment for side‑effects and emerging risk factors at each patient visit. 44